Found 147 results
Type [ Year(Asc)]
DG Ousterout, AM Kabadi, PI Thakore, P Perez-Pinera, MT Brown, WH Majoros, TE Reddy, and CA Gersbach. "Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases." Molecular Therapy : the Journal of the American Society of Gene Therapy 23, no. 3 (2015): 523-532.
N Farhang, JM Brunger, JD Stover, PI Thakore, BD Lawrence, F Guilak, CA Gersbach, LA Setton, and RD Bowles. "CRISPRi Immunomodulation for Tissue Engineering/Stem Cell Therapies Targeting Intervertebral Disc Degeneration." In Tissue Engineering. Part A, S170. Vol. 21. 2015.
IB Hilton, and CA Gersbach. "Enabling functional genomics with genome engineering." Genome Research 25, no. 10 (2015): 1442-1455.
AM Kabadi, PI Thakore, CM Vockley, DG Ousterout, TM Gibson, F Guilak, TE Reddy, and CA Gersbach. "Enhanced MyoD-induced transdifferentiation to a myogenic lineage by fusion to a potent transactivation domain." Acs Synthetic Biology 4, no. 6 (2015): 689-699.
IB Hilton, AM D'Ippolito, CM Vockley, PI Thakore, GE Crawford, TE Reddy, and CA Gersbach. "Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers." Nat Biotechnol 33, no. 5 (2015): 510-517.
JA Doudna, and CA Gersbach. "Genome editing: the end of the beginning." Genome Biology 16 (2015).
LR Polstein, P Perez-Pinera, DD Kocak, CM Vockley, P Bledsoe, L Song, A Safi, GE Crawford, TE Reddy, and CA Gersbach. "Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators." Genome Res 25, no. 8 (2015): 1158-1169.
PI Thakore, AM D'Ippolito, L Song, A Safi, NK Shivakumar, AM Kabadi, TE Reddy, GE Crawford, and CA Gersbach. "Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements." Nat Methods 12, no. 12 (2015): 1143-1149.
BO Diekman, PI Thakore, SK O'Connor, VP Willard, JM Brunger, N Christoforou, KW Leong, CA Gersbach, and F Guilak. "Knockdown of the cell cycle inhibitor p21 enhances cartilage formation by induced pluripotent stem cells." Tissue Engineering. Part A 21, no. 7-8 (2015): 1261-1274.
LR Polstein, and CA Gersbach. "A light-inducible CRISPR-Cas9 system for control of endogenous gene activation." Nature Chemical Biology 11, no. 3 (2015): 198-200.
DG Ousterout, AM Kabadi, PI Thakore, WH Majoros, TE Reddy, and CA Gersbach. "Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy." Nature Communications 6 (2015): 6244-.
J Black, A Adler, H Hutchinson, H Wang, G Pitt, K Leong, and C Gersbach. "Multiplex Gene Activation by CRISPR/Cas9-Based Transcription Factors for the Direct Conversion of Fibroblasts to a Neuronal Phenotype." In Molecular Therapy, S26. Vol. 23. 2015.
CL Frank, F Liu, R Wijayatunge, L Song, MT Biegler, MG Yang, CM Vockley, A Safi, CA Gersbach, GE Crawford et al. "Regulation of chromatin accessibility and Zic binding at enhancers in the developing cerebellum." Nat Neurosci 18, no. 5 (2015): 647-656.
TM Gibson, and CA Gersbach. "Single-molecule analysis of myocyte differentiation reveals bimodal lineage commitment." Integrative Biology : Quantitative Biosciences From Nano to Macro 7, no. 6 (2015): 663-671.
EA Josephs, DD Kocak, CJ Fitzgibbon, J McMenemy, CA Gersbach, and PE Marszalek. "Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage." Nucleic Acids Research 43, no. 18 (2015): 8924-8941.
CA Gersbach, and P Perez-Pinera. "Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine." Expert Opinion on Therapeutic Targets 18, no. 8 (2014): 835-839.
CA Gersbach, T Gaj, and CF Barbas. "Comparing genome editing technologies." Genetic Engineering & Biotechnology News 34, no. 5 (2014): 1, 32-34.
K High, PD Gregory, and C Gersbach. "CRISPR technology for gene therapy." Nature Medicine 20, no. 5 (2014): 476-477.
S Chakraborty, H Ji, AM Kabadi, CA Gersbach, N Christoforou, and KW Leong. "A CRISPR/Cas9-based system for reprogramming cell lineage specification." Stem Cell Reports 3, no. 6 (2014): 940-947.
AM Kabadi, and CA Gersbach. "Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression." Methods 69, no. 2 (2014): 188-197.
AM Kabadi, and CA Gersbach. "Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression." Methods (San Diego, Calif.) 69, no. 2 (2014): 188-197.
CA Gersbach. "Genome engineering: the next genomic revolution." Nature Methods 11, no. 10 (2014): 1009-1011.
LR Polstein, and CA Gersbach. "Light-inducible gene regulation with engineered zinc finger proteins." Methods in Molecular Biology (Clifton, N.J.) 1148 (2014): 89-107.
AM Kabadi, DG Ousterout, IB Hilton, and CA Gersbach. "Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector." Nucleic Acids Research 42, no. 19 (2014).
E Schulz, T Bergmann, M Gebbing, V Schildgen, O Schildgen, C Gersbach, and A Ehrhardt. "Mutation Detection Following Non-Homologous End Joining (NHEJ): A Comparison of Different Semi Quantitative and Quantitative Methods." In Molecular Therapy, S126-S127. Vol. 22. 2014.